Pharmaceutical Patents in Turkey: Patents, Data Exclusivity and the Bolar Exemption

Two forms of protection, on two clocks

For a pharmaceutical or life-sciences business, protecting a product in Turkey is rarely a single decision. It is the interaction of two distinct regimes. The first is the patent, granted by the Turkish Patent and Trademark Office (TURKPATENT), which protects the invention: the active compound, a formulation, a manufacturing process, or a medical use. The second is regulatory data exclusivity, which is not an IP right at all in the classic sense but a period during which the medicines regulator will not rely on an originator's registration data to approve a generic. These two protections are granted by different authorities and measured on different timelines, and the way they interact is a technical question rather than a fixed rule. Treating them as one thing is the most common planning error, so it helps to map both from the outset. The broader route into Turkish patent practice, including filing basics and the examination path, sits on the Turkey patents pillar.

The patent layer

A Turkish patent for a pharmaceutical invention is examined and granted much as any other patent, and the substantive requirements (novelty, inventive step, industrial applicability) follow the familiar international pattern. Turkish patent law is closely modelled on European norms, and in practice many originators reach Turkey through a European filing that is then validated or nationalised, or through the international PCT route. The patent term is the standard maximum period counted from filing, subject to maintenance, but you should confirm the exact statutory term and any renewal timing directly with TURKPATENT rather than assuming a fixed figure, because these details are technical and can change.

One point that matters a great deal in pharmaceuticals and is easy to get wrong: the availability and mechanics of any extension to compensate for regulatory review time (the kind of supplementary protection certificate familiar from the EU) should not be assumed. Whether such an extension exists in Turkey, and on what terms, is exactly the sort of version-specific question to put to TURKPATENT or to qualified local counsel before you build a lifecycle strategy on it. Do not treat any specific extension period as settled, and do not assume Turkey mirrors the EU supplementary protection certificate system.

The data-exclusivity layer

Separately from the patent, Turkey operates a regulatory data-exclusivity regime administered through the marketing-authorisation process rather than through TURKPATENT. The principle is that a generic applicant cannot lean on the originator's clinical and safety dossier to obtain approval until a protection period has run. This can matter independently of the patent, because it operates on the registration data rather than on the invention. That said, the Turkish regime is influenced by EU frameworks but materially different from them in scope and duration: it is generally understood to be a single, shorter protection period rather than the EU's staggered data-plus-market-exclusivity structure, to be tied to a first authorisation within a Customs Union country, and, importantly, to be bounded by the patent term. In other words, do not assume a data-exclusivity tail that outlasts the patent in the way it can in the EU. The precise length of the window, the conditions attached to it, and how it interacts with the patent term and with the reference product's authorisation are all technical and subject to change, so treat any period you have seen quoted as indicative only and confirm the current sequencing with the Turkish Medicines and Medical Devices Agency (Turkiye Ilac ve Tibbi Cihaz Kurumu, TITCK) or with local counsel. The key planning takeaway is that patent protection and data exclusivity are distinct mechanisms with distinct triggers, and their relative timing needs local confirmation rather than an imported EU assumption.

The Bolar-type research exemption

Turkey recognises a Bolar-type exemption, meaning that certain acts done to prepare a generic or biosimilar for regulatory approval (the studies, trials and administrative steps needed to secure a marketing authorisation) are treated as not infringing the originator's patent while it is still in force. This mirrors the logic behind the equivalent EU provision. For originators it means the runway to generic entry can begin before patent expiry, because competitors may lawfully do their approval groundwork in advance. For generics and biosimilar developers it is the mechanism that makes day-one launch planning realistic. The exact scope of the exempted acts is a matter of legal detail, so where a specific activity sits close to the line, take advice rather than relying on a general description.

How the EU influence shapes strategy, and where it stops

Because Turkish pharmaceutical IP draws on EU frameworks, a company already operating in Europe will recognise much of the architecture, and some of the same product and portfolio thinking carries over. That familiarity is a starting point, not a guarantee of matching outcomes. The data-exclusivity regime in particular is narrower and shorter than the EU equivalent and is understood to be capped by the patent term, so a lifecycle plan built on EU exclusivity assumptions can misjudge the Turkish position. The patent-term-extension question, the data-exclusivity mechanics, and the sequencing between the two each need local confirmation. For a side-by-side sense of the European baseline against which Turkey diverges, the EU patents overview is a useful companion read before you localise a strategy.

A note on scope, and how IPEnvoy can help

IPEnvoy is not a law firm and does not provide legal advice; this is general information only. Confirm the current position with TURKPATENT (and, for marketing authorisation and data exclusivity, the Turkish Medicines and Medical Devices Agency) and a qualified local IP professional before acting. If you would like to be introduced to a vetted IP firm in Turkey to pressure-test a pharmaceutical filing or lifecycle plan, IPEnvoy can help you find the right local expert.